BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 478429)

  • 1. Chromatographic pattern of gut glucagon-like immunoreactivity (GLI) in plasma before and during glucose absorption.
    Valverde I; Ghiglione M; Matesanz R; Casado S
    Horm Metab Res; 1979 May; 11(5):343-6. PubMed ID: 478429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of calcium and other salts upon the release of glucagon-like immunoreactivity from the gut.
    Böttger I; Faloona GR; Unger RH
    J Clin Invest; 1972 Apr; 51(4):831-6. PubMed ID: 5014613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of perfused rat intestine to characterise the glucagon-like immunoreactivity released into serosal secretions following stimulation by glucose.
    O'Connor FA; Conlon JM; Buchanan KD; Murphy RF
    Horm Metab Res; 1979 Jan; 11(1):19-23. PubMed ID: 428905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of canine gut glucagon-like immunoreactivity (GLI) and its insulin releasing activity.
    Ohneda A; Horigome K; Kai Y; Itabashi H; Ishii S; Yamagata S
    Horm Metab Res; 1976 May; 8(3):170-4. PubMed ID: 939462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal metabolism of gut glucagon-like immunoreactivity.
    Rovira A; López-Novoa JM; Zubiaur M; Matesanz R; Ghiglione M; Pascual JM; Valverde I
    Endocrinology; 1982 Jun; 110(6):2030-6. PubMed ID: 6896180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of insulin on the response of gut glucagon-like immunoreactivity (GLI) to oral glucose and food ingestion in the goose.
    Karmann H; Mialhe P
    Horm Metab Res; 1987 Feb; 19(2):47-52. PubMed ID: 3549502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma glucagon-like immunoreactivity (GLI) in dogs.
    Oneda A; Horigome K; Yanbe A; Ishii S; Itabashi H
    Tohoku J Exp Med; 1975 Apr; 115(4):337-43. PubMed ID: 1145615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of response of gut GLI to fat ingestion in dogs.
    Ohneda A; Kobayashi T; Nihei J
    Horm Metab Res; 1984 Dec; 16 Suppl 1():105-9. PubMed ID: 6398248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of extractable gut glucagon-like immunoreactivity (GLI) and its lipolytic activity.
    Horigome K; Oneda A; Maruhama Y; Abe R; Kai Y
    Horm Metab Res; 1977 Sep; 9(5):370-4. PubMed ID: 924346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatographic pattern of extrapancreatic glucagon and glucagon-like immunoreactivity before and during stimulation by epinephrine and participation of glucagon in epinephrine-induced hepatic glucose overproduction.
    Lickley HL; Kemmer FW; Gray DE; Kovacevic N; Hatton TW; Perez G; Vranic M
    Surgery; 1981 Aug; 90(2):186-94. PubMed ID: 6114573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose, insulin, pancreatic glucagon and glucagon-like immunoreactive materials in the plasma of normal and diabetic children. Effect of the initial insulin treatment.
    Matsuyama T; Hoffman WH; Dunbar JC; Foà NL; Foà PP
    Horm Metab Res; 1975 Nov; 7(6):452-6. PubMed ID: 1213649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose.
    Unger RH; Ohneda A; Valverde I; Eisentraut AM; Exton J
    J Clin Invest; 1968 Jan; 47(1):48-65. PubMed ID: 5638120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma glucagon and glucagon-like immunoreactive components in Type 1 (insulin-dependent) diabetic patients and normal subjects before and after an oral glucose load.
    Rovira A; Garrote FJ; Pascual JM; Salvador MG; Herrera Pombo JL; Valverde I
    Diabetologia; 1985 Feb; 28(2):80-6. PubMed ID: 3838521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional release of glucagon-like immunoreactivity from the intestine of the cat.
    Frame CM
    Horm Metab Res; 1977 Mar; 9(2):117-20. PubMed ID: 863376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity.
    Böttger I; Dobbs R; Faloona GR; Unger RH
    J Clin Invest; 1973 Oct; 52(10):2532-41. PubMed ID: 4738064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation of plasma glucagon-like immunoreactivity (GLI) in patients with liver cirrhosis.
    Watanabe A; Hashimoto M; Higashi T; Kobayashi M; Nakatsukasa H; Yamauchi Y; Watanabe M; Fujiwara M; Nagashima H
    J Med; 1986; 17(2):95-108. PubMed ID: 3473162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
    Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
    J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of phenformin upon the plasma pancreatic and gut glucagon-like immunoreactivity in diabetics.
    Czyzyk A; Heding LG; Malczewski B; Miedzinska E
    Diabetologia; 1975 Apr; 11(2):129-33. PubMed ID: 168107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic glucagon-like immunoreactivity in a pancreatectomized patient.
    Botha JL; Vinik AI; Child PT; Paul M; Jackson WP
    Horm Metab Res; 1977 May; 9(3):199-205. PubMed ID: 885471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the liver in glucagon metabolism.
    Jaspan JB; Huen AH; Morley CG; Moossa AR; Rubenstein AH
    J Clin Invest; 1977 Aug; 60(2):421-8. PubMed ID: 874100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.